- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07553559
Evaluation eines KI-basierten Diagnoseunterstützungstools für ältere Erwachsene in der Primärversorgung (INTERLACE)
Steigerung der diagnostischen Exzellenz für ältere Erwachsene durch kollektive Intelligenz und Nachahmungslernen
Older adults commonly experience diagnostic errors that may lead to direct harms and increased healthcare costs. Older adults are especially at risk because of higher rates of comorbidity burden, medical complexity, frailty, and cognitive impairment. An artificial intelligence (AI) clinical decision support system (CDSS) offer a promising approach to promote diagnostic excellence for older adults.
The purpose of this study is to assess the acceptability and feasibility of a new AI CDSS for older adults in primary care. The goal of this AI CDSS is to provide diagnostic support during primary care visits (i.e., help make timely and accurate diagnoses) and support communication amongst patients, doctors, and caregivers about the patient's health.
In this study, participants will use the AI CDSS in a primary care visit and review its suggestions for diagnoses and tests. Afterwards, they will complete a feedback survey and interview where they share their thoughts about and experience using the AI CDSS.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Alyssa M Sliwa, BA
- Telefonnummer: 215-746-3080
- E-Mail: alyssa.sliwa@pennmedicine.upenn.edu
Studieren Sie die Kontaktsicherung
- Name: Nicholas Bishop, BA
- E-Mail: nicholas.bishop@pennmedicine.upenn.edu
Studienorte
-
-
Pennsylvania
-
Philadephia, Pennsylvania, Vereinigte Staaten, 19104
- University of Pennsylvania
-
Kontakt:
- Clinical Research Coordinator
- Telefonnummer: 215-746-3080
- E-Mail: alyssa.sliwa@pennmedicine.upenn.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Clinicians
- Work in the University of Pennsylvania Health System
- Work in a primary care setting (i.e., Internal Medicine, Geriatric Medicine, Family Medicine, and Penn Primary Care)
- Actively treat adult patients who are 65 years old or older
Patients
- 65 years of age or older
- Have an upcoming encounter with a participating primary care clinician
- Indicate a new or worsening health concern that they wish to discuss at the upcoming encounter
Caregivers
- 18 years old or older
- Accompanying the participating patient during the encounter with the AI CDSS
- Identified by the patient as a caregiver
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Under the age of 18 years old
- Unable to provide informed consent in the opinion of the investigator
- Has a "Research Do Not Contact" status in the electronic health record
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Use of INTERLACE tool in primary care visit
All participants will be asked to use INTERLACE in their primary care visit. The tool will be presented on an handheld electronic device and may be used by patients, caregivers, and primary clinicians at each visit. First, the patient will input their current symptoms into INTERLACE. Then, using these symptoms, latest vital signs, and the patient's medical history, INTERLACE will make suggestions for diagnoses and tests. Patients, caregivers, and clinicians can view and discuss these suggestions together to arrive at a potential diagnosis. |
INTERLACE is an artificial intelligence-based clinical decision support tool. It uses a patient's medical history, vital signs, and current symptoms to make suggestions for diagnoses and tests. These suggestions can be considered and discussed amongst patients, caregivers, and clinicians during primary care visits to help find a good diagnosis for the patient's symptoms. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Feasibility of embedding the AI CDSS into a primary care visit
Zeitfenster: From enrollment to the end of the study interview, up to two weeks
|
Participants will complete a Feasibility of Intervention Measure (FIM) via feedback survey following the primary care visit. Responses are measured on a 5-point Likert scale. |
From enrollment to the end of the study interview, up to two weeks
|
|
Feasibility of embedding the AI CDSS into a primary care visit
Zeitfenster: From enrollment until the end of the study interview, up to two weeks
|
Feasibility will also be assessed through brief survey questions asking whether participants experienced any barriers to using INTERLACE, whether it was useful during the visit, and how long it was used (all measured on a 7-point Likert scale), as well as open-ended questions in a semi-structured interview. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Zeitfenster: From enrollment until the end of the study interview, up to two weeks
|
Participants will complete the Acceptability of Intervention Measure (AIM) via feedback survey after the primary care visit. Responses to the AIM are measured on a 5-point Likert scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Zeitfenster: From enrollment until the end of the study interview, up to two weeks
|
Participants will also complete a modified version of the Technology Acceptance model (TAM). Responses to the TAM are measured on a 7-point Likert scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Zeitfenster: From enrollment until the end of the study interview, up to two weeks
|
Participants will complete a Net Promoter Score assessing the likelihood that they would recommend the AI CDSS to others at the end of the survey. This will be measured on a 10-point scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Zeitfenster: From enrollment until the end of the study interview, up to two weeks
|
Acceptability will also be assessed through brief survey questions assessing whether INTERLACE caused distress (measured on a 7 point Likert scale), as well as open-ended questions in a semi-structured interview. |
From enrollment until the end of the study interview, up to two weeks
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Gary E Weissman, MD, MSPH, University of Pennsylvania
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- 852952
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .